Cara issues supplemental disclosures for Tvardi merger after stockholder lawsuits

Tvardi Therapeutics, Inc.

Received 13 demands and 2 lawsuits (filed Mar 5-6, 2025) claiming proxy omitted material info.
Combined company board to have 5 Tvardi designees, 1 Cara designee (Susan Shiff), 1 vacancy.
Piper Sandler valuation analyses updated with detailed peer comparisons and IPO precedent tables.
Cara denies violations but provides supplements to avoid litigation expense and merger disruption.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.